回盛生物(300871) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 230,412,076.04, representing a 12.03% increase compared to CNY 205,665,754.61 in the same period last year[6] - Net profit attributable to shareholders reached CNY 14,855,718.00, a significant increase of 634.03% from CNY 2,023,854.94 in the previous year[6] - The net profit after deducting non-recurring gains and losses was CNY 8,945,243.79, up 697.11% from CNY 1,122,203.66 year-on-year[6] - Basic and diluted earnings per share were both CNY 0.09, an increase of 800% compared to CNY 0.01 in the same period last year[6] - Total operating revenue for Q1 2023 was 16,631,467.48, a significant increase from 2,793,791.45 in Q1 2022, representing a growth of approximately 496%[26] - Net profit for Q1 2023 reached 14,855,718.00, compared to 2,023,854.94 in the same period last year, marking a year-over-year increase of about 634%[26] - Basic and diluted earnings per share for Q1 2023 were both 0.09, up from 0.01 in Q1 2022, indicating a substantial improvement in profitability[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,024,445,118.45, a 1.18% increase from CNY 2,989,114,303.25 at the end of the previous year[6] - The total assets as of March 31, 2023, amounted to CNY 3,024,445,118.45, up from CNY 2,989,114,303.25 at the beginning of the year, reflecting a growth of 1.2%[22] - The total current assets reached CNY 1,368,615,054.54, compared to CNY 1,351,475,288.90 at the start of the year, indicating an increase of 1.9%[20] - The total liabilities as of March 31, 2023, were CNY 1,468,156,374.06, slightly up from CNY 1,447,682,082.36 at the beginning of the year, showing an increase of 1.4%[22] - The total non-current assets were CNY 1,655,830,063.91, up from CNY 1,637,639,014.35, reflecting a growth of 1.1%[20] - Short-term borrowings rose to CNY 257,017,934.21 from CNY 220,084,829.04, an increase of 16.8%[21] - The company's retained earnings increased to CNY 391,076,854.19 from CNY 376,221,136.19, a growth of 3.9%[22] - The total equity attributable to the owners of the parent company was CNY 1,556,288,744.39, compared to CNY 1,541,432,220.89 at the beginning of the year, indicating an increase of 1.0%[22] Cash Flow - The company's cash flow from operating activities was negative at CNY -17,180,234.31, slightly worse than CNY -16,025,127.81 in the same period last year, reflecting a decrease of 7.21%[6] - Cash flow from operating activities showed a net outflow of -17,180,234.31, slightly worse than the -16,025,127.81 recorded in Q1 2022[29] - The net cash flow from investing activities improved by 76.49%, amounting to CNY -88,514,280.15 compared to CNY -376,449,232.15 in the previous year[14] - Cash flow from investing activities resulted in a net outflow of -88,514,280.15, compared to -376,449,232.15 in the previous year, indicating a reduction in cash burn[29] - The net cash flow from financing activities surged by 4,596.57% to CNY 64,595,118.87, primarily due to increased borrowings[14] - Cash flow from financing activities generated a net inflow of 64,595,118.87, a significant increase from 1,375,366.95 in Q1 2022, reflecting improved financing conditions[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,202, with the largest shareholder holding 49.86% of the shares[15] Government Subsidies - The company received government subsidies totaling CNY 3,980,605.72 during the reporting period, contributing to its financial performance[8] Operating Costs and Expenses - Total operating costs for Q1 2023 were 220,505,096.35, up from 201,486,255.25 in Q1 2022, indicating a rise of approximately 9.5%[25] - Research and development expenses for Q1 2023 were 9,286,444.32, slightly down from 9,754,406.16 in Q1 2022, showing a focus on cost management in R&D[25] Cash and Cash Equivalents - Cash and cash equivalents decreased to CNY 395,545,161.51 from CNY 424,044,443.62, representing a decline of 6.1%[19] - The company reported a total cash and cash equivalents balance of 237,472,437.22 at the end of Q1 2023, down from 575,070,614.85 at the end of Q1 2022[30] - The company received cash inflows from investment activities totaling 352,273,935.15, a significant increase from 30,353,258.20 in the previous year, indicating strong investment recovery[29]